The data will be presented at the
American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place
March 7-11, 2025, highlighting
HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities.
The recent case study will be highlighted that demonstrated the efficacy of
HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying
HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks.
NEW YORK, March 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, is excited to announce promising findings for its novel therapeutic candidate,
HT-001, a topical neurokinin 1 receptor (NK1R) antagonist, in the treatment of Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs).
The data will be presented at the
American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place
March 7-11, 2025, highlighting
HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities.
A recent case study demonstrated the efficacy of
HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying
HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks.
"These findings demonstrate the potential of
HT-001 as a safe and effective therapy for EGFR inhibitor-associated skin toxicities," said Robb Knie, CEO at Hoth Therapeutics. "With a significant unmet need for long-term, well-tolerated treatment options,
HT-001 could offer relief to cancer patients experiencing debilitating skin reactions."
HT-001 works by blocking the pro-inflammatory effects of the
Substance P (SP)-NK1R pathway, a key mediator of neurogenic inflammation. Preclinical research has shown that
HT-001 reduces inflammation and hair loss associated with EGFR inhibitor therapy. These latest clinical observations further support its potential role in dermatologic oncology.
Hoth Therapeutics is currently conducting a
Phase 2A clinical trial to evaluate the efficacy and safety of
HT-001 in a broader patient population. The trial will assess the treatment's effectiveness across varying severities of
EGFRi PPEs and explore its impact on other dermatologic manifestations induced by EGFR inhibitors.
For more information about
HT-001 and ongoing clinical trials, visit
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC Email: [email protected]
Phone: (678) 570-6791
SOURCE Hoth Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
